Wuhan Healthgen Biotechnology Corp. (SHSE: 688765)
Health Care · Biotechnology · CN
CN¥39.63
+1.82% today · -56.5% 1Y
Wuhan Healthgen Biotechnology Corp. (SHSE: 688765) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.10B.
Over the last twelve months the share price has lost 56.5%, trading between 32.61 and 132.03.
Tweenvest scores Wuhan Healthgen Biotechnology Corp. across four factors: quality 25/100, growth 100/100. Its strongest factor is growth.
688765 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.10B
- Revenue (TTM)
- $3.29M
- P/E
- —
- EPS
- -0.59
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CN¥132.03
- 52-week low
- CN¥32.61
- Avg volume (3M)
- —
- Shares outstanding
- 357.50M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.